Literature DB >> 7866680

The function of the hypothalamic-pituitary-adrenal axis in Alzheimer's disease. Response to insulin hypoglycaemia.

J T O'Brien1, I Schweitzer, D Ames, M Mastwyk, P Colman.   

Abstract

BACKGROUND: To investigate an association between HPA axis dysfunction, depression and cognitive impairment, we assessed subjects with mild Alzheimer's disease (AD).
METHOD: Sixteen non-depressed subjects with AD according to NINCDS/ADRDA criteria and 18 normal controls underwent the insulin hypoglycaemia (IH) test and the dexamethasone suppression test (DST).
RESULTS: The AD subjects showed a blunted response of adrenocorticotrophic hormone (ACTH) to IH compared with controls (P = 0.019). ACTH response (area under curve) correlated with a score for cognitive ability (CAMCOG) (r = 0.64, P < 0.01). AD subjects had a shorter time to peak cortisol level than controls (P = 0.004), although total cortisol response was normal.
CONCLUSIONS: The AD subjects show evidence of adrenal hyper-responsiveness and normal immediate (rate-sensitive) glucocorticoid feedback. An association between HPA axis dysfunction and organic brain pathology in AD subjects may be mediated by cell loss in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866680     DOI: 10.1192/bjp.165.5.650

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  3 in total

1.  [Hypoglycemia despite hyperglycemia. Is a cerebral glucose deficiency possible even with raised blood sugar levels?].

Authors:  G Erdös; R Lobmann; B Wolcke; C Werner
Journal:  Anaesthesist       Date:  2005-07       Impact factor: 1.041

Review 2.  Neural circuitry in the regulation of adrenal corticosterone rhythmicity.

Authors:  William C Engeland; Michelle M Arnhold
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

3.  Aberrant stress response associated with severe hypoglycemia in a transgenic mouse model of Alzheimer's disease.

Authors:  W A Pedersen; C Culmsee; D Ziegler; J P Herman; M P Mattson
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.